Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 424

1.

2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members:.

J Hypertens. 2018 Oct;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940.

PMID:
30234752
2.

The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.

Jaspers NEM, Ridker PM, Dorresteijn JAN, Visseren FLJ.

Curr Opin Lipidol. 2018 Sep 17. doi: 10.1097/MOL.0000000000000554. [Epub ahead of print]

PMID:
30234556
3.

Editor's Choice - Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis.

Huibers AE, Westerink J, de Vries EE, Hoskam A, den Ruijter HM, Moll FL, de Borst GJ.

Eur J Vasc Endovasc Surg. 2018 Sep;56(3):322-333. doi: 10.1016/j.ejvs.2018.05.012. Epub 2018 Jun 29. Review.

PMID:
30196814
4.

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease.

Kofink D, Muller SA, Patel RS, Dorresteijn JAN, Berkelmans GFN, de Groot MCH, van Solinge WW, Haitjema S, Leiner T, Visseren FLJ, Hoefer IE, Asselbergs FW; SMART Study Group.

PLoS One. 2018 Sep 7;13(9):e0202682. doi: 10.1371/journal.pone.0202682. eCollection 2018.

5.

2018 ESC/ESH Guidelines for the management of arterial hypertension.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group .

Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. No abstract available.

PMID:
30165516
6.

Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension.

Van Der Sande NGC, Blankestijn PJ, Visseren FLJ, Beeftink MM, Voskuil M, Westerink J, Bots ML, Spiering W.

J Hypertens. 2018 Aug 1. doi: 10.1097/HJH.0000000000001885. [Epub ahead of print]

PMID:
30074565
7.

Evaluation of an activity monitor for use in pregnancy to help reduce excessive gestational weight gain.

Lemmens PMC, Sartor F, Cox LGE, den Boer SV, Westerink JHDM.

BMC Pregnancy Childbirth. 2018 Jul 31;18(1):312. doi: 10.1186/s12884-018-1941-8.

8.

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.

Schrover IM, van der Graaf Y, Spiering W, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2018 Sep;25(14):1548-1557. doi: 10.1177/2047487318790722. Epub 2018 Jul 27.

PMID:
30052066
9.

Combined use of polypill components in patients with type 2 diabetes mellitus.

Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group.

Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.

PMID:
30033753
10.

Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients.

Sharif S, Bots ML, Schalkwijk C, Stehouwer CDA, Visseren FLJ, Westerink J; SMART study group.

Nutr Metab Cardiovasc Dis. 2018 Jun 13. pii: S0939-4753(18)30192-3. doi: 10.1016/j.numecd.2018.06.004. [Epub ahead of print]

PMID:
30017437
11.

The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications.

de Graaf G, Postmus D, Westerink J, Buskens E.

Cost Eff Resour Alloc. 2018 Jun 18;16:23. doi: 10.1186/s12962-018-0105-z. eCollection 2018.

12.

Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, Visseren FLJ, Imholz BPM, Roeters van Lennep JE, Huijgen R, Kastelein JJP, Hovingh GK.

J Clin Lipidol. 2018 Jul - Aug;12(4):972-980.e1. doi: 10.1016/j.jacl.2018.04.002. Epub 2018 Apr 18.

PMID:
29934068
13.

Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.

van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group.

J Hypertens. 2018 Sep;36(9):1865-1873. doi: 10.1097/HJH.0000000000001785.

PMID:
29878973
14.

The amount of calcifications in pseudoxanthoma elasticum patients is underestimated in computed tomographic imaging; a post-mortem correlation of histological and computed tomographic findings in two cases.

Vos A, Kranenburg G, de Jong PA, Mali WPTM, Van Hecke W, Bleys RLAW, Isgum I, Vink A, Spiering W.

Insights Imaging. 2018 Aug;9(4):493-498. doi: 10.1007/s13244-018-0621-6. Epub 2018 Jun 1.

15.

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.

Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN.

BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309.

16.

The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort.

Kranenburg G, Baas AF, de Jong PA, Asselbergs FW, Visseren FLJ, Spiering W; SMART study-group.

Eur J Med Genet. 2018 May 22. pii: S1769-7212(17)30881-9. doi: 10.1016/j.ejmg.2018.05.020. [Epub ahead of print]

PMID:
29800625
17.

Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes.

Hanssen NMJ, Westerink J, Scheijen JLJM, van der Graaf Y, Stehouwer CDA, Schalkwijk CG; SMART Study Group.

Diabetes Care. 2018 Aug;41(8):1689-1695. doi: 10.2337/dc18-0159. Epub 2018 May 21.

PMID:
29784769
18.

Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients.

Østergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J; SMART Study Group.

Diabetes Metab. 2018 May 8. pii: S1262-3636(18)30083-1. doi: 10.1016/j.diabet.2018.04.006. [Epub ahead of print]

PMID:
29784563
19.

The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.

Krikke M, Tesselaar K, van den Berk GEL, Otto SA, Freriks LH, van Lelyveld SFL, Visseren FJL, Hoepelman AIM, Arends JE.

HIV Clin Trials. 2018 Apr;19(2):75-83. doi: 10.1080/15284336.2018.1455366.

PMID:
29770748
20.

Endovascular Baroreflex Amplification for Resistant Hypertension.

van Kleef MEAM, Bates MC, Spiering W.

Curr Hypertens Rep. 2018 May 9;20(5):46. doi: 10.1007/s11906-018-0840-8. Review.

Supplemental Content

Loading ...
Support Center